Health Trials

About this trial

This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients.

The investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate.

The second is related to peripheral inflammation, specifically joint synovitis, blood cytokines/chemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.

Eligibility criteria

Qualifiers

Adults ≥18 years < 75 years.

Right-handed (to reduce neuroimaging heterogeneity).

Disqualifiers

Inability to provide written informed consent.

Severe physical impairment (e.g. blindness, deafness, paraplegia).

Pregnant or breast feeding.

Severe claustrophobia precluding MRI.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

1
Neil Basu Glasgow United Kingdom

Sponsors and collaborators

NHS Greater Glasgow and Clyde

Lead sponsor

Lakefront Biotherapeutics NV

Collaborator

Source ClinicalTrials.gov